ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4961
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

Part 2

Late-Breaker Discussion Series

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

ACC 2024 — Late-breaker host Dr. Harriette Van Spall (McMaster University, CA) sits down with Dr. James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).

This phase 3 multicenter, randomized, placebo-controlled, 2-part study evaluated the safety and efficacy of an aldose reductase inhibitor (ARI), AT-001, in patients with diabetic cardiomyopathy. Findings presented first at ACC.24 showed that AT-001 was safe and well-tolerated but did not result in a statistically significant difference in peak VO2 in patients with diabetic cardiomyopathy and reduced exercise capacity, however, it should be noted that the participants of ARISE-HF had well controlled type II diabetes mellitus (A1c=6.98%) which might not reflect outcomes in individuals with diabetic cardiomyopathy more generally.

Recorded remotely from Boston and Hamilton, 2024.

Support: This is an independent content produced by Radcliffe Cardiology.

Editor: Mirjam Boros
Videographer: Mike Knight, Tom Green

Faculty Biographies

Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile
James L Januzzi

James L Januzzi

Director of the Cardiac Intensive Care Unit

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

Dr Januzzi was the top-ranked graduate in his class at New York Medical College. He completed an internship and residency at Brigham and Women’s Hospital prior to performing a clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, where he also completed a fellowship in cardiac ultrasound. 

He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure.  He has served as the Cardiology Consultant to the Boston Red Sox since 2005.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.